Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
Rhea-AI Summary
Venus Concept, a global leader in medical aesthetic technology, has regained compliance with Nasdaq's Minimum Equity Requirement as of June 4, 2024. The company was previously issued a deficiency notice on May 31, 2023, for not meeting the minimum stockholders' equity requirement of $2.5 million, as per their March 31, 2023, Quarterly Report. To rectify this, Venus Concept completed a $35 million debt-to-equity transaction on May 28, 2024. As a result, the company met the compliance requirements verified by Nasdaq. Venus Concept will be under mandatory panel monitoring until June 4, 2025, according to Nasdaq Listing Rule 5815(d)(4)(B).
Positive
- Regained compliance with Nasdaq's Minimum Equity Requirement.
- Completed a $35 million debt-to-equity transaction.
- Avoided delisting from the Nasdaq Stock Market.
- Company will be monitored for compliance until June 4, 2025.
Negative
- Previously fell below the minimum $2.5 million stockholders' equity requirement.
- Issued a deficiency notice on May 31, 2023.
- Mandatory monitoring by Nasdaq until June 4, 2025 indicates ongoing risk.
News Market Reaction – VERO
On the day this news was published, VERO gained 19.71%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that on June 4, 2024, it was notified by the Nasdaq Stock Market LLC (“Nasdaq”) that the Company had regained compliance with the stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Minimum Equity Requirement”). Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor through June 4, 2025.
The Nasdaq Staff originally issued the Company a deficiency notice on May 31, 2023, citing that stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
